NxStage Medical, Inc. (NASDAQ:NXTM) saw unusually large options trading on Friday. Traders acquired 4,004 put options on the stock. This represents an increase of approximately Infinity compared to the average daily volume of 0 put options.

In related news, President Joseph E. Turk, Jr. sold 1,000 shares of the stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $29.26, for a total transaction of $29,260.00. Following the sale, the president now owns 74,903 shares of the company’s stock, valued at approximately $2,191,661.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction dated Friday, October 20th. The stock was sold at an average price of $27.50, for a total value of $96,250.00. Following the sale, the senior vice president now directly owns 15,270 shares in the company, valued at approximately $419,925. The disclosure for this sale can be found here. Insiders have sold a total of 18,600 shares of company stock valued at $526,162 in the last quarter. 4.70% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the business. Swiss National Bank raised its holdings in shares of NxStage Medical by 11.9% in the 3rd quarter. Swiss National Bank now owns 122,700 shares of the medical device company’s stock valued at $3,387,000 after acquiring an additional 13,000 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of NxStage Medical in the 3rd quarter valued at about $202,000. IndexIQ Advisors LLC purchased a new stake in shares of NxStage Medical in the 3rd quarter valued at about $2,139,000. Gabelli Funds LLC purchased a new stake in shares of NxStage Medical in the 3rd quarter valued at about $4,941,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of NxStage Medical during the 3rd quarter valued at about $7,073,000. 92.22% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NxStage Medical (NASDAQ NXTM) opened at $26.65 on Monday. NxStage Medical has a 1-year low of $20.45 and a 1-year high of $30.80.

NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The firm had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. During the same quarter last year, the firm posted ($0.03) EPS. The company’s revenue was up .0% compared to the same quarter last year. analysts forecast that NxStage Medical will post -0.06 EPS for the current fiscal year.

A number of analysts recently issued reports on the company. Jefferies Group LLC cut NxStage Medical from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $33.00 to $30.00 in a report on Tuesday, August 8th. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Thursday, August 10th. BTIG Research cut NxStage Medical from a “buy” rating to a “neutral” rating in a report on Friday, August 11th. Northland Securities reissued a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a report on Monday, August 7th. Finally, Canaccord Genuity cut NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price objective on the stock. in a report on Monday, August 7th. Two analysts have rated the stock with a sell rating and eight have given a hold rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $30.25.

ILLEGAL ACTIVITY WARNING: “Traders Buy High Volume of NxStage Medical Put Options (NXTM)” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/06/traders-buy-high-volume-of-nxstage-medical-put-options-nxtm.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.